Solifenacin
- Generic Name
- Solifenacin
- Brand Names
- Vesicare
- Drug Type
- Small Molecule
- Chemical Formula
- C23H26N2O2
- CAS Number
- 242478-37-1
- Unique Ingredient Identifier
- A8910SQJ1U
- Background
Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily.
Solifenacin was granted FDA approval on 19 November 2004.
- Indication
Solifenacin tablets are indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Overactive Bladder Syndrome (OABS)
- Associated Therapies
- -
VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2015-01-16
- Lead Sponsor
- Advanced Research Network
- Target Recruit Count
- 8
- Registration Number
- NCT01777217
- Locations
- 🇺🇸
Century Cancer Center, Houston, Texas, United States
A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence
- Conditions
- Interventions
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- Allergan
- Target Recruit Count
- 356
- Registration Number
- NCT01767519
Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)
- First Posted Date
- 2012-12-11
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT01747577
A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients
- First Posted Date
- 2012-12-07
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 223
- Registration Number
- NCT01745094
Treatment of Urge Urinary Incontinence in Women After Failure of Cesa or Vasa
- Conditions
- Interventions
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- Klinikum der Universität Köln
- Target Recruit Count
- 120
- Registration Number
- NCT01737918
- Locations
- 🇩🇪
Abt. Beckenbodenchirurgie der Universitäts-Frauenklinik Köln, Köln, NRW, Germany
Surgical vs. Medical Treatment of Urge Urinary Incontinence in Women
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- Klinikum der Universität Köln
- Target Recruit Count
- 120
- Registration Number
- NCT01737411
- Locations
- 🇩🇪
Abt. Beckenbodenchirugie der Universitäts-Frauenklinik Köln, Köln, NRW, Germany
Bacterial Genomic Sequencing in Overactive Bladder
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Loyola University
- Target Recruit Count
- 134
- Registration Number
- NCT01642277
- Locations
- 🇺🇸
Loyola University Chicago Health Sciences Division, Maywood, Illinois, United States
A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.
- Conditions
- Interventions
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 1887
- Registration Number
- NCT01638000
- Locations
- 🇦🇲
Site: 37404, Yerevan, Armenia
🇦🇲Site: 37402, Yerevan, Armenia
🇦🇹Site: 43013, Linz, Austria
Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug
- First Posted Date
- 2012-06-25
- Last Posted Date
- 2012-11-15
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT01627145
- Locations
- 🇨🇳
No 8, Chung-Shan South Road,, Taipei, Taiwan
Solifenacin Succinate Versus Fesoterodine A Comparison Trial for Urgency Symptoms
- Conditions
- Interventions
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2012-05-16
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 60
- Registration Number
- NCT01595152
- Locations
- 🇮🇱
Rambam Health Care Campus, Haifa, Israel
🇮🇱Belinson, Petach Tikva, Israel
🇮🇱Asaf harofeh, Tel Aviv, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.